Effects of Dry Needling on Spasticity, Functions, Balance and Independence Level in Patients With Stroke

NCT ID: NCT03863678

Last Updated: 2019-12-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 42 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-05-12
• Study Completion Date: 2019-12-01

Brief Summary

The aim of this study is to investigate the effects of dry needling method in addition to neurodevelopmental therapy on spasticity, upper and lower extremity functions, balance and independence level in patients with stroke who have spasticity.

Detailed Description

The aim of this study is to investigate the effects of dry needling method in addition to neurodevelopmental therapy on spasticity, upper and lower extremity functions, balance and independence level in patients with stroke who have spasticity. In this study, goniometric measurement, Modified Ashworth Scale, Nine Hole Peg Test, 10 Meter Walking Test, Fullerton Advanced Balance Scale and Functional Independence Scale will be used for outcome measurement. The participants will be randomised into two groups; Group 1 will receive NDT and Group 2 will receive both NDT and dry needling therapy. Both groups will be given 45 minutes of NDT, 3 sessions per week in 4 weeks period (total of 12 sessions). Group 2 will also receive dry needling therapy 3 sessions per week in 4 weeks period (total of 12 sessions). Dry needling will be applied on M. Gastrocnemius, M.Quadriceps, M.Flexor Carpi Radialis and M.Biceps Brachii muscles. The application time on each muscle will be 60 seconds (sec). Fast in and fast out technique will be used for dry needling therapy. All patients will be measured before treatment (T1) and after treatment (T3). An inter-measurement will be performed after the treatment session (T2) in addition to T1 and T3 measurements in the Group 2, to evaluate the acute effects of dry needling therapy. No additional treatment will be applied to the Group 1. All assessments will be performed by the same physiotherapist.

Conditions

Stroke; CVA (Cerebrovascular Accident)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Neurodevelopmental therapy

Group 1 will only receive Neurodevelopmental therapy (NDT), for 12 sessions.

Group Type: EXPERIMENTAL

Neurodevelopemental therapy (NDT)

Intervention Type: OTHER

NDT treatment will be given for 45 minutes, 3 sessions per week in 4 weeks period (total of 12 sessions).

Neurodevelopemental therapy and dry needling therapy

Group 2 will receive Neurodevelopmental therapy (NDT) and dry needling therapy, for 12 sessions.

Group Type: EXPERIMENTAL

Neurodevelopemental therapy (NDT) and dry needling

Intervention Type: OTHER

NDT treatment will be given for 45 minutes, 3 sessions per week in 4 weeks period (total of 12 sessions). Dry needling will be applied on M. Gastrocnemius, M.Quadriceps, M.Flexor Carpi Radialis, and M.Biceps Brachii muscles, 60 seconds (sec) for each muscle groups at the end of the NDT treatment.

Interventions

Neurodevelopemental therapy (NDT)

NDT treatment will be given for 45 minutes, 3 sessions per week in 4 weeks period (total of 12 sessions).

Intervention Type: OTHER

Neurodevelopemental therapy (NDT) and dry needling

NDT treatment will be given for 45 minutes, 3 sessions per week in 4 weeks period (total of 12 sessions). Dry needling will be applied on M. Gastrocnemius, M.Quadriceps, M.Flexor Carpi Radialis, and M.Biceps Brachii muscles, 60 seconds (sec) for each muscle groups at the end of the NDT treatment.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• First time stroke,
• Patients who has spasticity due to stroke,
• At least 6 months after stroke,
• Individuals between the ages of 18-75 will be included in the study.

Exclusion Criteria

• Any contraindication for dry needling (eg, anticoagulants, infections, bleeding, etc.),
• Having diabetes,
• Having cardiovascular diseases,
• Having any other neurological problems,
• Application of Botox within 6 months prior to the study,
• Individuals included in another treatment program will not be included in the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Eastern Mediterranean University

OTHER

Sponsor Role: lead

Responsible Party

Kübra Küçüktepe

Msc Physiotherapist

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Gozde Iyigün, PhD

Role: STUDY_DIRECTOR

Eastern Mediterranean University

Locations

Eastern Mediterranean University

Famagusta, North Cyprus Via Mersin 10 Turkey, Cyprus

Countries

Cyprus

Other Identifiers

KK 1695

Identifier Type: -

Identifier Source: org_study_id